Does Lithium Increase Triglycerides?
Yes, lithium therapy can increase triglyceride levels, though the evidence shows this effect is variable and may depend on individual metabolic vulnerability rather than occurring uniformly in all patients.
Evidence from Clinical Guidelines and Drug Labels
The Endocrine Society's 2012 clinical practice guideline on hypertriglyceridemia does not list lithium among the drugs known to raise triglyceride levels 1. The guideline specifically identifies alcohol, thiazide diuretics, beta-blockers, oral estrogens, retinoids, bile acid sequestrants, protease inhibitors, immunosuppressants (sirolimus), certain second-generation antipsychotics (clozapine, olanzapine, risperidone, quetiapine), and sertraline as triglyceride-raising medications, but lithium is notably absent from this comprehensive list.
The FDA drug label for lithium does not specifically mention hypertriglyceridemia or lipid abnormalities as adverse effects 2.
Evidence from Clinical Research
Despite the absence of lithium in major guidelines, recent research demonstrates that lithium can increase triglycerides in some patients:
A 2026 study of 152 euthymic bipolar patients found that triglyceride levels increased significantly (P<0.001) after 3 months of lithium therapy 3. Importantly, this study revealed that patients with lower baseline inflammatory-nutritional reserve (measured by Prognostic Nutritional Index) were more vulnerable to atherogenic worsening, suggesting individual biological susceptibility rather than a uniform effect.
A 2007 study showed that lithium treatment increased atherogenic lipids, with LDL-cholesterol significantly elevated during lithium monotherapy 4. When combined with olanzapine, the lipid effects were even more pronounced.
A 2022 study found significant differences in triglyceride levels between bipolar patients receiving lithium versus valproic acid, with positive correlations between triglycerides and treatment duration 5.
Contradictory Evidence
One older study from 1976 found that long-term lithium treatment had no influence on serum triglycerides in 12 patients after 6 months 6. However, this small, dated study is outweighed by more recent and larger investigations.
Protective Findings
Interestingly, a 2026 study found that higher serum lithium levels (>0.6 mEq/L) were associated with lower carotid intima-media thickness, suggesting potential anti-atherosclerotic effects 7. This paradoxical finding indicates that while lithium may raise triglycerides acutely, adequate therapeutic levels might confer long-term cardiovascular protection through other mechanisms.
Clinical Implications
Monitor lipid panels in patients starting lithium therapy, particularly:
- Those with baseline metabolic vulnerability (low albumin, poor nutritional status)
- Patients with pre-existing hypertriglyceridemia or metabolic syndrome
- Individuals with obesity or family history of dyslipidemia
- Those on concurrent medications that raise triglycerides (especially antipsychotics)
The triglyceride elevation with lithium appears to be:
- Variable between individuals (not universal)
- Potentially related to baseline metabolic reserve
- More pronounced when combined with certain antipsychotics
- Possibly offset by maintaining therapeutic lithium levels (>0.6 mEq/L)
Do not discontinue lithium solely for mild triglyceride elevation, as the mood-stabilizing benefits typically outweigh metabolic risks. Instead, implement lifestyle modifications (weight management, dietary changes, exercise) and consider lipid-lowering therapy if triglycerides exceed 200 mg/dL or if multiple cardiovascular risk factors are present 8.